- Home
- SDRL vs IRON Comparison
SDRL vs IRON Comparison
Compare SDRL & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDRL | IRON |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SDRL | IRON |
|---|---|---|
| Price | $46.10 | $71.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $56.00 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 633.6K | 336.5K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,437,000,000.00 | N/A |
| Revenue This Year | $5.22 | N/A |
| Revenue Next Year | $14.20 | $283.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.75 | N/A |
| 52 Week Low | $19.60 | $40.00 |
| 52 Week High | $48.99 | $99.50 |
Technical Indicators
Market Signals| Indicator | SDRL | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 65.34 |
| Support Level | $41.63 | $70.29 |
| Resistance Level | $48.99 | $82.70 |
| Average True Range (ATR) | 1.79 | 2.69 |
| MACD | -0.18 | 0.95 |
| Stochastic Oscillator | 38.65 | 98.22 |
Price Performance
Historical ComparisonAbout SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.